SCHEMBL4877463

SCHEMBL4877463

O=C(O)c1cc2c(s1)c(C1CCCCC1)c(-c1ccc3nc(-c4c(F)cccc4F)ccc3c1)n2CC(=O)N1CCC(N2CCCC2)CC1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.36
POLB P06746 1/20 0.36
TSHR P16473 1/20 0.36
TP53 P04637 1/20 0.35
CBX7 O95931 2/20 0.35
CDYL2 Q8N8U2 2/20 0.35
CDYL Q9Y232 2/20 0.35
CDY1; CDY1B Q9Y6F8 1/20 0.35
IRAK4 Q9NWZ3 3/20 0.35
CYP2C9 P11712 3/20 0.33
KMT2A Q03164 2/20 0.33
ALDH1A1 P00352 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
SMO Q99835 1/20 0.33
ACHE P22303 1/20 0.33
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.32
MEN1 O00255 1/20 0.32
TDP1 Q9NUW8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4868332 0.95 ALDH1A1 (0.37) GAATSHRKMT2AALDH1A1SMN1; SMN2
SCHEMBL4875667 0.93 SMO (0.33) GAAKMT2AALDH1A1SMN1; SMN2SMO
SCHEMBL4876782 0.92 GAA (0.37) GAAPOLBTSHRTP53CBX7
SCHEMBL4878071 0.91 TP53 (0.35) GAAPOLBTSHRTP53CBX7
SCHEMBL4877285 0.91 MAPT (0.36) GAAPOLBTSHRTP53CBX7
SCHEMBL4872058 0.89 GAA (0.40) GAAPOLBTSHRTP53CBX7
SCHEMBL4876592 0.89 DPP4 (0.32) GAAKMT2AALDH1A1SMN1; SMN2
SCHEMBL4874410 0.89 TRPV4 (0.38) GAAPOLBTSHRIRAK4
SCHEMBL4870793 0.88 CBX7 (0.37) GAAPOLBTSHRCBX7CDYL2
SCHEMBL4875205 0.88 IRAK4 (0.36) GAAPOLBTSHRTP53CBX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080051384-A1 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. 2008-02-28 US disclosed
US-20080051384-A1 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. 2008-02-28 US disclosed
US-20080051384-A1 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. 2008-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051384-A1 ANTIVIRAL AGENTS EIF2AK2, MAVS, ZC3HAV1 GAA 66/4885POLB 327/4885TSHR 4492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.